2024 AACR Annual Meeting Successfully Convened； APS Pharma’s Latest Research Attracted Wide Attention.

The 115th American Association for Cancer Research (AACR) Annual Meeting was held in San Diego, USA, April 5-10, 2024. …

CDE Approved the IND Application of the Next-generation RET inhibitor APS03118

On July 21, 2022, the IND application of the next-generation RET inhibitor APS03118, an innovative drug independently developed by Applied Pharmaceutical Science, was approved by the Center for Drug Evaluation (CDE). APS03118 is developed to treat adult patients with RET-positive unresectable locally advanced or metast...…

CDE Accepted the IND Application of the Next-generation RET inhibitor APS03118

On May 10, 2022, the IND application of the next-generation RET inhibitor APS03118, an innovative drug independently developed by Applied Pharmaceutical Science, was accepted by the Center for Drug Evaluation (CDE). According to the acceptance announcement, the drug name is APS03118 capsule, and the acceptance number i...…

Applied Pharmaceutical Science Released the Critical Preclinical Data of Next-generation RET Inhibitor APS03118

On April 8,2022, Applied Pharmaceutical Science disclosed for the first time the critical preclinical data of the next-generation RET inhibitor APS03118 at AACR 2022 annual meeting. The data shows that APS03118 is a highly selective next-generation RET inhibitor that strongly inhibits multiple RET aberrances in vitro a...…

Latest Preclinical Data of the Next-generation RET inhibitor APS03118 will be released at AACR 2022 Annual Meeting

Latest preclinical data of the next-generation RET inhibitor APS03118 will be formally released during April 8 to 13, 2022 at AACR Annual Meeting, that will be held in New Orleans, Louisiana, USA. Applied Pharmaceutical Science will for the first time disclose the key preclinical data of APS03118 in the form of electro...…

FDA Approves pralsetinib for RET+ Lung Cancer

The FDA has approved pralsetinib(formerly known as BLU-667; GAVRETO™) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer, September 4, 2020…

FDA Approves Selpercatinib for RET+ Lung and Thyroid Cancers

The FDA has approved selpercatinib (formerly known as LOXO-292; Retevmo™) capsules for the treatment of patients with lung cancer or thyroid cancer harboringRETalterations.This marks the first treatment approved to targetRETgene alterations.…